Back to Search
Start Over
Exploring the role of adipsin in statin-induced glucose intolerance: a prospective open label study.
- Source :
-
Drug metabolism and personalized therapy [Drug Metab Pers Ther] 2020 Apr 06; Vol. 35 (1). Date of Electronic Publication: 2020 Apr 06. - Publication Year :
- 2020
-
Abstract
- Background Evidence from the literature, highlights the increased risk of developing glucose intolerance and type 2 diabetes mellitus (T2DM) with statin therapy. In addition, few animal studies demonstrate that adipsin secreted from adipocytes plays a crucial role in insulin secretion and the development of T2DM. Methods To further explore the role of serum adipsin, in this prospective open label study, 55 newly diagnosed dyslipidemic patients were enrolled. Before starting statin therapy, liver function test (LFT), kidney function test (KFT), lipid profile, glycemic parameters [glycated hemoglobin A (HbA1c), fasting blood sugar (FBS), and postprandial blood sugar (PPBS)], serum insulin, and serum adipsin were estimated. Then these patients were prescribed statin (i.e. atorvastatin, rosuvastatin, or pitavastatin) and after 12 weeks of therapy, all the above investigations were repeated. Results After 12 weeks of statin therapy, the LFT and KFT values remained unchanged and lipid parameters showed significant improvement. But the glycemic parameters deranged significantly (p < 0.001), i.e. FBS, PPBS, and HbA1c increased by 12.49% (102.99 ± 20.76 mg/dL), 24.72% (147.71 ± 47.29 mg/dL), and 21.43% (6.38 ± 1.34%), respectively. On the other hand, the baseline adipsin (2.73 ± 1.99 ng/mL) and insulin (16.13 ± 12.50 mIU/L) levels reduced significantly (p < 0.0001) to 1.43 ±1.13 ng/mL and 6.91 ± 5.93 mIU/L, respectively. The reduction in serum adipsin also showed a positive correlation with reduction in serum insulin (r = 0.85; p < 0.0001). None of the patients experienced any significant adverse effect or reaction leading to discontinuation of therapy. Conclusions There might be an association between reduction in adipsin and development of glucose intolerance by statin therapy.
- Subjects :
- Adolescent
Adult
Aged
Cholesterol, LDL blood
Complement Factor D analysis
Diabetes Mellitus, Type 1 chemically induced
Diabetes Mellitus, Type 1 diagnosis
Diabetes Mellitus, Type 2 chemically induced
Diabetes Mellitus, Type 2 diagnosis
Dyslipidemias chemically induced
Dyslipidemias diagnosis
Female
Glucose Intolerance chemically induced
Glucose Intolerance diagnosis
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects
Male
Middle Aged
Prospective Studies
Young Adult
Complement Factor D metabolism
Diabetes Mellitus, Type 1 metabolism
Diabetes Mellitus, Type 2 metabolism
Dyslipidemias metabolism
Glucose Intolerance metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 2363-8915
- Volume :
- 35
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Drug metabolism and personalized therapy
- Publication Type :
- Academic Journal
- Accession number :
- 32229661
- Full Text :
- https://doi.org/10.1515/dmpt-2020-0101